ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone781-345-9001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$89.79 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableNot Optionable
ConforMIS (NASDAQ:CFMS) Frequently Asked Questions
What is ConforMIS's stock symbol?
ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."
How were ConforMIS's earnings last quarter?
ConforMIS Inc (NASDAQ:CFMS) posted its earnings results on Wednesday, February, 6th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.04. The medical instruments supplier earned $22.05 million during the quarter, compared to analyst estimates of $21.45 million. ConforMIS had a negative return on equity of 91.73% and a negative net margin of 48.30%. View ConforMIS's Earnings History.
When is ConforMIS's next earnings date?
What price target have analysts set for CFMS?
5 equities research analysts have issued 12 month price targets for ConforMIS's shares. Their forecasts range from $2.50 to $3.00. On average, they anticipate ConforMIS's share price to reach $2.8750 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for ConforMIS.
What is the consensus analysts' recommendation for ConforMIS?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.
What are Wall Street analysts saying about ConforMIS stock?
Here are some recent quotes from research analysts about ConforMIS stock:
- 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (3/18/2019)
- 2. BTIG Research analysts commented, "Ongoing OUS Headwinds While CFMS 2Q18 results were a bit below our expectations (rev. of $19.1M (+3% Y/Y,+2% xFx) vs. BTIG/Consensus of $19.3M/$19.4M respectively, product rev. increased Y/Y for the first time since 1Q17, growing 5% to $18.0M. Mgmt. is making progress on US commercialization (albeit slower than investors will prefer). OUS continues to be challenged in Germany but mgmt. noted recent OUS sales leadership hires that may open up a few countries in 2H18. Mgmt. commentary on payor acceptance of CFMS products indicates increasing positive traction amongst some payers but CFMS is still not where it wants to be on rep growth, which missed the 20% growth target slightly. On the call, mgmt. announced plans to reduce OpEx while shuffling its product pipeline around." (8/2/2018)
Has ConforMIS been receiving favorable news coverage?
News articles about CFMS stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ConforMIS earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.
Are investors shorting ConforMIS?
ConforMIS saw a increase in short interest in February. As of February 28th, there was short interest totalling 1,573,885 shares, an increase of 130.1% from the February 15th total of 684,043 shares. Based on an average daily trading volume, of 1,204,909 shares, the days-to-cover ratio is presently 1.3 days. Approximately 2.9% of the shares of the stock are short sold. View ConforMIS's Current Options Chain.
Who are some of ConforMIS's key competitors?
Some companies that are related to ConforMIS include Establishment Labs (ESTA), RTI Surgical (RTIX), Sientra (SIEN), Invacare (IVC), Lakeland Industries (LAKE), COLLPLANT HOLDI/S (CLGN), Rewalk Robotics (RWLK), NanoVibronix (NAOV), Wound Management Technologies (WNDM), Precision Therapeutics (AIPT), Bionik Laboratories (BNKL), Histogenics (HSGX), Allied Healthcare Products (AHPI), Avitar (AVTI) and Halyard Health (HYH).
What other stocks do shareholders of ConforMIS own?
Who are ConforMIS's key executives?
ConforMIS's management team includes the folowing people:
- Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
- Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
- Dr. Daniel Steines M.D., MS, Consultant (Age 50)
- Mr. Ed Kilgallen, VP of Operations
- Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
When did ConforMIS IPO?
(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
Who are ConforMIS's major shareholders?
ConforMIS's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Two Sigma Investments LP (0.23%), Two Sigma Advisers LP (0.22%), Acadian Asset Management LLC (0.20%), Millennium Management LLC (0.16%) and Gabelli Funds LLC (0.16%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.
Which institutional investors are selling ConforMIS stock?
CFMS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP and Two Sigma Advisers LP. Company insiders that have sold ConforMIS company stock in the last year include Bradley Langdale, Daniel Steines, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Insider Buying and Selling for ConforMIS.
Which institutional investors are buying ConforMIS stock?
How do I buy shares of ConforMIS?
Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ConforMIS's stock price today?
One share of CFMS stock can currently be purchased for approximately $2.39.
How big of a company is ConforMIS?
ConforMIS has a market capitalization of $162.33 million and generates $89.79 million in revenue each year. The medical instruments supplier earns $-43,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.
What is ConforMIS's official website?
How can I contact ConforMIS?
ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]
MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
